Sumanta K. Pal: Misha Beltran highlighting role of DLL3 in neuroendocrine prostate cancer

Sumanta K. Pal shared on X:

“Crystal clear talk from Misha Beltran highlighting role of DLL3 in neuroendocrine prostate cancer. Although some of the early data with tarlatamab may not be very supportive, eager to see MK6070 – interesting signal in NEPC.”

Source: Sumanta K. Pal/X

More posts featuring Sumanta K. Pal on oncodaily.com

Sumanta K. Pal, MD, is a medical oncologist and an expert in genitourinary cancers at the City of Hope Comprehensive Cancer Center in Los Angeles. He serves as the Vice Chair of Academic Affairs, Professor and co-director of the Kidney Cancer Program and leads the Kidney and Bladder Cancer Disease Team at City of Hope. He specialises in kidney, bladder, and prostate cancers.